December 29, 2022 10:29 AM ESTUpdated 03:47 PM

News wrap: Equillium axes Metacrine merger; Two pharmas pen ADC deals

ENDPOINTS

Immunobiology biotech Equillium announced a “mutual termination” of an anticipated merger with Rich Heyman-chaired Metacrine a little over three months after …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

News wrap: Equillium axes Metacrine merger; Two pharmas pen ADC deals

ENDPOINTS

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

CBER's deputy director departs as staff shakeup continues

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

News wrap: Equi­l­li­um ax­es Metacrine merg­er; Two phar­mas pen ADC deals

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

News wrap: Equillium axes Metacrine merger; Two pharmas pen ADC deals